- December 11, 2017 14:00 (CET)Regulatory
Today, December 11, 2017, Cyxone AB (publ.) held an extraordinary general meeting. Below is an overview of the motions decided upon. All motions were taken with the necessary majority of votes.
- December 6, 2017 08:30 (CET)Regulatory
- November 23, 2017 08:55 (CET)Regulatory
Shareholders in Cyxone AB (publ.), 559020-5471, are hereby invited to an extraordinary general meeting at Setterwalls Advokatbyrå AB, Stortorget 23, in Malmö, on Monday, December 11, 2017 at 10:00AM.
- November 23, 2017 08:50 (CET)Regulatory
As previously announced, Cyxone acquired Rabeximod from OxyPharma in June 2017. Rabeximod has undergone Phase 2 trials in patients with moderate to severe rheumatoid arthritis in which significant improvements in the condition's symptoms were discovered four weeks after the completion of the formal (12 week) trial period.
Existing Rabeximod can be used in Cyxone's planned Phase 2b study in patients with rheumatoid arthritisNovember 6, 2017 16:54 (CET)Regulatory
Cyxone has analysed the Rabeximod that was previously manufactured by OxyPharma for clinical trials at Syntagon AB. Results show that the existing substance, despite having been stored for several years, can be used in Cyxone's upcoming Phase 2b study in patients with rheumatoid arthritis.
- October 26, 2017 10:21 (CEST)Regulatory
- October 26, 2017 10:07 (CEST)Regulatory
In co-operation with Taiwan-based Eurofins Panlabs Discovery Services, Cyxone has investigated whether T20K has the capacity to influence receptors or other cellular functions to shed light on the substance's potential side effects.
- October 13, 2017 17:02 (CEST)Regulatory
In collaboration with the Medical University of Vienna, Cyxone is set to conduct a study into inflammatory bowel disease involving a cyclotide in established animal models. The study will begin early in 2018.
- October 6, 2017 15:30 (CEST)Regulatory
Cyxone has licensed patent applications at various stages of approval in Europe, North America and Australia. In the US, our patent is approved and in other markets patent applications are well on the way to being approved. In Australia, our patent application was accepted in July, since when the company has submitted a final version and paid the required approval fee.
- October 5, 2017 18:50 (CEST)Regulatory
Due to the interview conducted with Cyxone's CEO by BioStock/Monocl on Thursday, September 28, the company wishes to clarify references made about the extent to which two Phase 2 trials may be equated with a Phase 3 trial.